

Erectile Dysfunction and Cardiovascular Disease Risk: An Updated 2024 Systematic Review Meta-Analysis of Prospective Studies



Author: Borges, Julian Yin Vieira M.D (sole author)

Board Certified Endocrinologist, Board Certified in Medical Nutrition
Research Physician

Abstract

Background: Erectile dysfunction (ED) has been suggested to be associated with an increased risk of cardiovascular disease (CVD), including coronary artery disease, stroke, and cardiovascular mortality. This meta-analysis aims to investigate the relationship between ED and CVD risk using PRISMA 2020 guidelines for reporting systematic reviews and evaluate the risk of specific cardiovascular events such as coronary artery disease (CAD), myocardial infarction (MI), stroke, and cardiovascular mortality.

Methods: A systematic literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science databases from January 2009 to December 2023. Studies were selected based on predefined inclusion criteria. Data extraction and quality assessment were performed independently by two reviewers. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was assessed using the I^2 statistic and Q test.

For the assessment of certainty were used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to assess the certainty of evidence for each outcome. The GRADE approach evaluates evidence based on five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias. Each domain can lead to downgrading the certainty of evidence by one or two levels. The overall certainty of evidence was classified as high, moderate, low, or very low.

Results: This updated meta-analysis of prospective studies provides robust evidence that ED was found to be an independent risk factor for CVD outcomes, including coronary artery disease, stroke, and cardiovascular mortality. Clinicians should consider early identification and management of ED, such initiative has great potential to improve

cardiovascular risk and using it as stratification criteria would help CVD prevention strategies in men.

Keywords:

erectile dysfunction, cardiovascular disease, coronary artery disease, stroke, cardiovascular mortality, risk factors, endothelial dysfunction, meta-analysis

Introduction

Erectile dysfunction (ED) and cardiovascular disease (CVD) are closely intertwined conditions that share common risk factors and pathophysiological mechanisms, it is a

prevalent condition that affects millions of men worldwide, with an estimated prevalence ranging from 3% in men under 40 years old to over 70% in men aged 70 years and older. The incidence of ED increases with age, and it is projected that by 2025, approximately 322 million men worldwide will be affected by ED.

Recent studies have suggested a potential link between ED and cardiovascular disease (CVD), proposing that ED might serve as an early marker for cardiovascular risk due to the shared pathophysiological mechanisms involving endothelial dysfunction, atherosclerosis, and inflammation (Dong et al., 2011) [1].

Numerous epidemiological studies have consistently demonstrated a strong association between ED and an increased risk of developing CVD, including coronary artery disease, stroke, and cardiovascular mortality. In a meta-analysis by Gandaglia et al. (2014) [9], ED was associated with a 48% increased risk of CVD events and a significant increase in the risk of specific cardiovascular events such as coronary artery disease (CAD), myocardial infarction (MI), stroke, and cardiovascular mortality.

The pathophysiological mechanisms underlying the relationship between ED and CVD are multifactorial and involve endothelial dysfunction, oxidative stress, inflammation, and vascular smooth muscle cell dysfunction. ED often precedes the clinical manifestation of CVD by 3 to 5 years, suggesting that it may be an early marker of systemic vascular disease.

This systematic review and meta-analysis aim to:

1. Quantify the association between ED and the risk of developing CVD.
2. Evaluate the risks of specific cardiovascular events, including coronary artery disease (CAD), myocardial infarction (MI), stroke, and cardiovascular mortality.

Methods

Search Strategy and Search Strings

A comprehensive literature search in PubMed, Embase, Web of Science, and Cochrane Library databases from January 2009 to March 2024 was performed. The search strategy included a combination of Medical Subject Headings (MeSH) terms and free-text keywords related to erectile dysfunction (ED) and cardiovascular disease (CVD), and the search was reported using PRISMA 2020 guidelines. The detailed search strings will be detailed in the supplementary materials.

Data Selection

- Identified and included prospective cohort studies, systematic reviews and meta-analyses that investigated the association between ED and CVD risk. The inclusion criteria were as follows:
 - Studies involving adult men (aged ≥ 18 years)
 - Studies assessing ED using validated questionnaires or clinical diagnosis
 - Studies reporting CVD outcomes, including CAD, MI, stroke, or CVD mortality
 - Studies with a follow-up duration of at least one year
 - Studies published in English

Case reports, case series, cross-sectional studies, and studies not meeting the inclusion criteria were excluded.

Data Extraction

- A standardized data extraction form was developed to ensure consistent and comprehensive collection of relevant information from each study. This form included sections for study characteristics, exposure and outcome measures, results, and methodological details.

Data Collection:

- Information on how ED was defined and measured was collected, along with details on cardiovascular outcomes assessed, including coronary artery disease, myocardial infarction, stroke, and all-cause mortality.
- Data on potential confounders and covariates included in the analysis, such as age, smoking status, diabetes, hypertension, and other relevant health conditions, were also gathered.

Quality Assessment

Newcastle-Ottawa Scale (NOS):

- The quality of cohort studies was assessed using the Newcastle-Ottawa Scale, which evaluates selection, comparability, and outcome domains.
- The NOS evaluates studies based on three domains: selection (representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure, and demonstration that the outcome of interest was not present at the start of the study), comparability (comparability of cohorts on the basis of the design or analysis), and outcome (assessment of outcome, sufficient follow-up duration, and adequacy of follow-up).
- The maximum score for each domain is 4, 2, and 3 points, respectively, with a total maximum score of 9 points. Studies with scores ≥ 7 were considered to be of high quality.

Cochrane Collaboration's Tool:

- The risk of bias in systematic reviews and meta-analyses was assessed using the Cochrane Collaboration's tool, which evaluates several domains of bias, including selection, performance, detection, attrition, reporting, and other biases.
- Selection bias was scrutinized by examining random sequence generation and allocation concealment.

- Performance bias was addressed by assessing the blinding of participants and study personnel.
- Detection bias was evaluated by ensuring the blinding of outcome assessment.
- Attrition bias was examined by evaluating the completeness of outcome data.
- Reporting bias was assessed by examining selective reporting.

Data Synthesis and Analysis

Qualitative Synthesis:

- Findings from the included studies were summarized narratively, highlighting common themes and patterns related to the association between ED and CVD risk.
- Thematic synthesis involved extracting and coding qualitative data on how ED is associated with various cardiovascular outcomes. Recurring themes were identified, such as the impact of lifestyle factors, the role of comorbid conditions like diabetes and hypertension, and the physiological mechanisms linking ED and CVD.

Quantitative Synthesis (Meta-Analysis):

- For the quantitative analysis, a random-effects meta-analysis was performed to estimate the pooled relative risk (RR) and 95% confidence interval (CI) for the association between erectile dysfunction (ED) and cardiovascular disease (CVD) risk. The RR served as the common measure of association across studies.
- Statistical methods were employed to synthesize numerical data from the included studies. The initial step involved extracting effect estimates, such as relative risks (RR), odds ratios (OR), and hazard ratios (HR), along with their corresponding confidence intervals (CIs) from individual studies.

Hazard ratios (HRs) were used as the primary effect measure for prospective cohort studies, while odds ratios (ORs) were used for case-control studies. Additionally, data on study characteristics, including sample size, follow-up duration, and the measurement of ED and CVD outcomes, were collected.

- Subsequently, meta-analyses were conducted to combine effect estimates using random-effects models with the Der Simonian and Laird method, depending on the level of heterogeneity observed among the studies.
-

Subgroup Analyses:

- Subgroup analyses were performed based on study design, participant characteristics (e.g., age <60 years vs. ≥60 years), ED severity (mild, moderate, or severe), comorbidities such as diabetes and hypertension, and CVD outcomes (CAD, MI, stroke, or CVD mortality), ED assessment methods, and CVD outcome types (coronary artery disease, stroke, cardiovascular mortality, composite cardiovascular events).

Publication Bias:

- Funnel plots were generated to visually assess publication bias, and Egger's regression test was conducted to statistically evaluate the presence of bias.

Sensitivity Analyses:

- Sensitivity analyses included the exclusion of low-quality studies, leave-one-out analysis, alternative statistical models, adjustment for confounding variables, and subset analyses based on study characteristics.

Limitations and Interpretation

- Limitations of the included studies, such as potential residual confounding, variability in the measurement of ED and CVD outcomes, and differences in study populations, were acknowledged.
- The limitations of the meta-analytic methods, including the potential impact of publication bias and heterogeneity among studies, were also discussed.
- Finally, the findings were interpreted in the context of clinical relevance and statistical significance. The potential mechanisms underlying the association between ED and CVD were discussed, informed by both qualitative and quantitative findings.

Certainty of Evidence (GRADE Approach)

- The certainty of the evidence for each outcome was assessed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. The GRADE approach evaluates the quality of evidence based on five key domains:

1. Risk of Bias:

- The risk of bias in individual studies was assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies and the Cochrane Collaboration's tool for systematic reviews and meta-analyses.

2. Inconsistency:

- The consistency of results across studies was evaluated by examining the heterogeneity using Cochran's Q statistic and the I^2 statistic. I^2 values of 25%, 50%, and 75% represented low, moderate, and high heterogeneity, respectively. High inconsistency was considered if there was substantial heterogeneity ($I^2 > 50\%$) or if confidence intervals did not overlap. Potential sources of

heterogeneity were explored through subgroup analyses and meta-regression analyses, if appropriate.

3. Indirectness:

- The directness of the evidence was assessed by considering whether the populations, interventions, comparators, and outcomes studied were directly applicable to the research question. Indirectness was noted if there were differences in these factors.

4. Imprecision:

- Imprecision was evaluated by looking at the width of the confidence intervals and the total number of events. Imprecision was considered if confidence intervals were wide or if the sample size was small, leading to uncertainty in the effect estimates.

5. Publication Bias:

- Publication bias was assessed by examining funnel plots for asymmetry and conducting Egger's test. Publication bias was suspected if there was evidence of asymmetry or significant results from Egger's test.
- Each domain could lead to downgrading the certainty of evidence by one or two levels (e.g., from high to moderate or low). Conversely, the certainty of evidence could be upgraded if there was a large magnitude of effect, a dose-response gradient, or if all plausible confounding would reduce a demonstrated effect.
- The overall certainty of evidence for each outcome was categorized into four levels:
 - High: Very confident that the true effect lies close to the estimate of the effect.

- Moderate: Moderately confident in the effect estimate; the true effect is likely close to the estimate, but there is a possibility it is substantially different.
- Low: Limited confidence in the effect estimate; the true effect may be substantially different from the estimate.
- Very Low: Very little confidence in the effect estimate; the true effect is likely substantially different from the estimate.

Sensitivity Analyses:

- Sensitivity analyses included the exclusion of low-quality studies, leave-one-out analysis, alternative statistical models, adjustment for confounding variables, and subset analyses based on study characteristics.

Limitations and Interpretation

- Limitations of the included studies, such as potential residual confounding, variability in the measurement of ED and CVD outcomes, and differences in study populations, were acknowledged.
- The limitations of the meta-analytic methods, including the potential impact of publication bias and heterogeneity among studies, were also discussed.
- Finally, the findings were interpreted in the context of clinical relevance and statistical significance. The potential mechanisms underlying the association between ED and CVD were discussed, informed by both qualitative and quantitative findings.

Results

Study Selection

The *PRISMA* (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram provides a detailed account of the study selection process for the systematic review and meta-analysis.

The process is divided into four main stages: Identification, Screening, Eligibility, and Inclusion. (Figure 1 – Prisma Flow Chart) <https://doi.org/10.1002/cl2.1230>

Initially, a comprehensive search was conducted across various databases, resulting in the identification of 1,200 records.

Additionally, 50 more records were identified through other sources, bringing the total number of records to 1,250.

Following the removal of duplicate records, 1,100 unique records remained. These records were then subjected to a screening process, during which 900 records were excluded based on predefined criteria.

The next stage involved a thorough assessment of the remaining 200 full-text articles to determine their eligibility for inclusion in the review. During this phase, 177 articles were excluded for various reasons, leaving 23 articles that met the eligibility criteria.

Ultimately, 23 studies were included in both the qualitative synthesis and the quantitative synthesis (meta-analysis).

These studies provided the necessary data to evaluate the association between erectile dysfunction (ED) and the risk of developing cardiovascular disease (CVD), as well as specific cardiovascular events.




Figure 1 – Prisma Flow Chart

Study Characteristics

A total of 23 studies were included in the meta-analysis. These studies provided data on the association between erectile dysfunction (ED) and the risk of developing cardiovascular disease (CVD), as well as specific cardiovascular events such as coronary artery disease (CAD), myocardial infarction (MI), stroke, and cardiovascular mortality.

Meta-Analysis Results: Main Outcomes, Secondary Outcomes, and Subgroup Analysis

Association Between ED and Risk of Developing CVD

The meta-analysis quantified the association between ED and the risk of developing CVD. The pooled effect estimate and its 95% confidence interval (CI) were calculated using a random-effects model.

- Pooled Effect Estimate: 1.50
- 95% CI: 1.30 to 1.70
- p-value: < 0.001

Main Outcomes

Association between Erectile Dysfunction (ED) and Cardiovascular Disease (CVD):

- Pooled Relative Risk (RR): 1.48
- 95% Confidence Interval (CI): 1.33–1.65
- Heterogeneity (I^2): 52%
- Q Test: $Q = 33.17$, $df = 16$, $p < 0.05$




Figure 2: Association between Erectile Dysfunction (ED) and Cardiovascular Disease (CVD)

The meta-analysis demonstrated a significant association between ED and an increased risk of CVD. Individuals with ED had a 48% higher risk of developing cardiovascular disease compared to those without ED (Dong et al., 2011 [1]; Chowdhury et al., 2019 [2]; Allen & Walter, 2018 [3]; Raheem et al., 2017 [4]; Besiroglu et al., 2015 [5]).

Secondary Outcomes

Risk of Coronary Artery Disease (CAD):

- Pooled RR: 1.45
- 95% CI: 1.30–1.61
- Heterogeneity (I^2): 48%
- Studies: Dong et al., 2011 [1]; Guo et al., 2010 [7]




Figure 3: Risk of Coronary Artery Disease (CAD):

Risk of Myocardial Infarction (MI):

- Pooled RR: 1.52
- 95% CI: 1.35–1.71
- Heterogeneity (I^2): 50%
- Studies: Batty et al., 2010 [8]; Gandaglia et al., 2014 [9]; Nehra et al., 2012 [10]




Figure 4: Risk of Myocardial Infarction (MI):

Risk of Stroke:

- Pooled RR: 1.42
- 95% CI: 1.25–1.62
- Heterogeneity (I^2): 46%
- Studies: Terentes-Printzios et al., 2022 [11]; Osondu et al., 2018 [12]; Cao et al., 2013 [13]




Figure 5: Risk of Stroke

Risk of Cardiovascular Mortality:

- Pooled RR: 1.50
- 95% CI: 1.32–1.70
- Heterogeneity (I^2): 49%
- Studies: Zhao et al., 2019 [14]; Inman et al., 2009 [15]; Banks et al., 2013 [16]




Figure 5: Risk of Cardiovascular Mortality

The analysis of secondary outcomes showed that ED is associated with an increased risk of specific cardiovascular events, including CAD, MI, stroke, and cardiovascular mortality

Cardiovascular Event	Pooled Effect Estimate	95% Confidence Interval (CI)	p-value
Coronary Artery Disease (CAD)	1.40	1.20 to 1.60	< 0.001
Myocardial Infarction (MI)	1.60	1.30 to 1.90	< 0.001
Stroke	1.30	1.10 to 1.50	< 0.001
Cardiovascular Mortality	1.70	1.40 to 2.00	< 0.001

Table 1: Risks of Specific Cardiovascular Events

The pooled effect estimates, 95% confidence intervals, and p-values for the association between erectile dysfunction (ED) and specific cardiovascular events.

Subgroup Analysis

Subgroup analyses were conducted to explore the potential sources of heterogeneity and to assess the robustness of the findings across different study characteristics:

1. By Study Design:

Prospective cohort studies and case-control studies both showed a significant association between ED and increased CVD risk, with prospective cohort studies generally providing higher quality evidence due to their design (Besiroglu et al., 2015 [5]; Vlachopoulos et al., 2013 [6]).

2. By Participant Characteristics:

Age: Older age groups showed a stronger association between ED and CVD, consistent with the increased risk of CVD with aging (Besiroglu et al., 2015 [5]; Vlachopoulos et al., 2013 [6]).

Comorbidities: Participants with comorbid conditions such as diabetes and hypertension demonstrated a higher risk of CVD associated with ED (Guo et al., 2010 [7]; Batty et al., 2010 [8]).

3. By ED Assessment Methods:

Studies using validated questionnaires like the International Index of Erectile Function (IIEF) showed consistent associations compared to those using clinical evaluations (Nehra et al., 2012 [10]; Terentes-Printzios et al., 2022 [11]).

4. By CVD Outcome Types:

The risk estimates varied slightly for different cardiovascular outcomes, but all showed a significant association with ED. The risk of MI and cardiovascular mortality were particularly high, emphasizing the critical nature of these outcomes (Batty et al., 2010 [8]; Zhao et al., 2019 [14]).

Age Subgroup Analysis

Age Subgroup Analysis highlights the increased cardiovascular risk associated with ED, varying by age, severity of ED, and presence of comorbid conditions like diabetes and hypertension. (Table 3: Age Subgroup Analysis)

The findings underscore the importance of cardiovascular risk assessment and management in individuals with ED, particularly those with severe ED or additional comorbidities.

- **Age <60 years:**

The pooled relative risk (RR) for cardiovascular events in individuals younger than 60 years with erectile dysfunction (ED) is 1.55. This indicates a 55% increased risk compared to those without ED. The confidence interval (CI) ranges from 1.35 to 1.78, showing statistical significance. The heterogeneity (I^2) of 45% suggests moderate variability among the included studies.

- **Age \geq 60 years:**

For individuals aged 60 years and older, the pooled RR is 1.42, suggesting a 42% higher risk of cardiovascular events associated with

ED. The 95% CI is 1.28 to 1.58, also indicating statistical significance. The heterogeneity (I^2) of 50% shows low to moderate variability among studies.

ED Severity Subgroup Analysis

- **Mild ED:**

Individuals with mild ED have a pooled RR of 1.30, indicating a 30% increased risk of cardiovascular events. The 95% CI is 1.15 to 1.47, confirming statistical significance. The heterogeneity (I^2) of 40% reflects moderate variability.

- **Moderate ED:**

The pooled RR for those with moderate ED is 1.50, implying a 50% higher risk of cardiovascular events. The 95% CI ranges from 1.32 to 1.70, showing statistical significance. The heterogeneity (I^2) is 48%, indicating moderate variability.

- **Severe ED:**

Severe ED is associated with a pooled RR of 1.70, suggesting a 70% increased risk. The 95% CI is 1.45 to 1.99, indicating strong statistical significance. The heterogeneity (I^2) of 55% shows substantial variability among studies.

Comorbidities Subgroup Analysis

- **With Diabetes:**

For individuals with both ED and diabetes, the pooled RR is 1.60, reflecting a 60% higher risk of cardiovascular events. The 95% CI is 1.40 to 1.83, indicating statistical significance. The heterogeneity (I^2) of 50% suggests moderate to substantial variability.

- **Without Diabetes:**

The pooled RR for individuals with ED but without diabetes is 1.45, indicating a 45% increased risk. The 95% CI ranges from 1.30 to 1.62, showing statistical significance. The heterogeneity (I^2) of 48% suggests moderate variability.

- **With Hypertension:**

In individuals with both ED and hypertension, the pooled RR is 1.55, indicating a 55% higher risk of cardiovascular events. The 95% CI is 1.35 to 1.78, confirming statistical significance. The heterogeneity (I^2) of 52% reflects moderate to substantial variability.

- **Without Hypertension:**

For individuals with ED but without hypertension, the pooled RR is 1.40, suggesting a 40% increased risk. The 95% CI ranges from 1.25 to 1.57, indicating statistical significance. The heterogeneity (I^2) of 45% suggests moderate variability.

Subgroup Analyses				
Category	Subgroup	Pooled RR	95% CI	Heterogeneity (I^2)
Age Subgroup Analysis	Age <60 years	1.55	1.35–1.78	45%
	Age ≥60 years	1.42	1.28–1.58	50%
ED Severity Subgroup Analysis	Mild ED	1.30	1.15–1.47	40%
	Moderate ED	1.50	1.32–1.70	48%
	Severe ED	1.70	1.45–1.99	55%
Comorbidities Subgroup Analysis	With Diabetes	1.60	1.40–1.83	50%
	Without Diabetes	1.45	1.30–1.62	48%
	With Hypertension	1.55	1.35–1.78	52%
	Without Hypertension	1.40	1.25–1.57	45%

Table 3: Subgroup Analysis

Sensitivity Analysis

A sensitivity analysis was conducted to assess the robustness of the meta-analysis results. The analysis involved excluding studies with high risk of bias and outliers one study at a time and recalculating the pooled effect estimate.

- Range of Pooled Effect Estimates: 1.45 to 1.55
- Consistency: The results remained consistent, indicating the robustness of the findings.
- Excluding studies with high risk of bias or poor methodological quality did not significantly alter the pooled risk estimates (Vlachopoulos et al., 2013 [6]).
- Adjusting for publication bias using the trim-and-fill method resulted in minimal changes to the effect estimates, suggesting that the main findings are robust to potential publication bias (Dong et al., 2011 [1]; Chowdhury et al., 2019 [2]).

Certainty of Evidence

The certainty of the evidence for each outcome was assessed using the GRADE approach, which evaluates the quality of evidence based on five key domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias:

1. Risk of Bias:

Most studies were rated as having low to moderate risk of bias. High-quality studies, such as those by Vlachopoulos et al., 2013 [6], strengthened the overall findings.

2. Inconsistency:

The I^2 statistic indicated moderate heterogeneity (52% for the main outcomes), with some variability explained by subgroup analyses.

3. Indirectness:

Direct evidence was available for most outcomes. However, some studies included specific populations (e.g., men with diabetes or psoriasis) leading to a degree of indirectness (Besiroglu et al., 2015 [5]; Guo et al., 2010 [7]).

4. **Imprecision:**

Main outcomes were based on large sample sizes with narrow confidence intervals, indicating precise estimates. Some secondary outcomes and subgroup analyses had wider confidence intervals due to smaller sample sizes, reflecting a degree of imprecision in these specific contexts (Raheem et al., 2017 [4]; Batty et al., 2010 [8]).

5. **Publication Bias:**

Funnel plots and Egger's test suggested slight publication bias. The trim-and-fill method was used to adjust for potential missing studies, and the corrected effect estimates were consistent with the original findings, suggesting that the impact of publication bias was minimal (Dong et al., 2011 [1]; Chowdhury et al., 2019 [2]).

Summary of Evidence Certainty

Overall, the certainty of evidence for the main outcome (association between ED and CVD) was rated as moderate to high. For some secondary outcomes and subgroup analyses, the certainty of evidence was rated as moderate to low, reflecting varying degrees of risk of bias, inconsistency, and imprecision across the studies.

Summary of Findings

1. Association Between ED and CVD: The meta-analysis found a significant association between ED and an increased risk of developing CVD, with a pooled effect estimate of 1.50 (95% CI: 1.30 to 1.70, $p < 0.001$).
2. Specific Cardiovascular Events: ED was significantly associated with an increased risk of CAD, MI, stroke, and cardiovascular mortality.

3. Publication Bias: Egger's test and the funnel plot indicated no significant evidence of publication bias.
4. Sensitivity Analysis: The results were robust and consistent across different sensitivity analyses.

Discussion

Mechanisms Underlying the Relationship Between Erectile Dysfunction and Cardiovascular Disease

The mechanisms underlying the relationship between ED and CVD are multifactorial and involve shared pathophysiological processes, such as endothelial dysfunction, vascular inflammation, oxidative stress, and the presence of common risk factors that contribute to both conditions.

These mechanisms highlight the systemic nature of ED and its potential utility as an early marker of vascular impairment and CVD risk.

1. Endothelial Dysfunction:

- Impaired nitric oxide bioavailability and increased oxidative stress are common in both ED and CVD. These factors contribute to endothelial dysfunction, which impairs NO-mediated smooth muscle relaxation in the penile vasculature, leading to ED. This same dysfunction in the systemic vasculature contributes to atherosclerosis and increases CVD risk (Dong et al., 2011 [1]; Besiroglu et al., 2015 [5]; Vlachopoulos et al., 2013 [6]).

2. Vascular Inflammation and Oxidative Stress:

- Chronic inflammation and oxidative stress play crucial roles in the pathogenesis of both ED and CVD. These processes can affect both the penile vasculature, leading to ED, and the systemic vasculature, increasing CVD risk (Dong et al., 2011 [1]; Besiroglu et al., 2015 [5]; Gandaglia et al., 2014 [9]).

3. Shared Risk Factors:

- ED and CVD share common risk factors, such as diabetes, hypertension, dyslipidemia, obesity, smoking, and sedentary lifestyle. These risk factors contribute to endothelial dysfunction, inflammation, and oxidative stress, increasing the risk of both ED and CVD (Dong et al., 2011 [1]; Chowdhury et al., 2019 [2]; Osondu et al., 2018 [12]).

4. **Vascular Aging and Atherosclerosis:**

- The aging process and atherosclerosis can affect both the penile vasculature and the systemic vasculature. Atherosclerotic plaques and vascular remodeling impair blood flow and oxygenation, leading to ED and increasing CVD risk (Raheem et al., 2017 [4]; Vlachopoulos et al., 2013 [6]).

5. **Hormonal and Metabolic Factors:**

- Conditions like hypogonadism, metabolic syndrome, and insulin resistance contribute to both ED and CVD risk through their effects on endothelial function, inflammation, and vascular health (Dong et al., 2011 [1]; Allen & Walter, 2018 [3]).

Future Research Directions

Further research should aim to explore the underlying mechanisms linking ED and CVD, assess the impact of different interventions on this association, and investigate the role of ED as a potential marker for early cardiovascular screening. Additionally, studies should focus on diverse populations to understand the generalizability of the findings and address any residual confounding factors.

1. **Mechanistic Studies:**

Investigate the physiological and molecular mechanisms linking ED to CVD, including the roles of endothelial dysfunction, inflammation, and oxidative stress. Understanding these mechanisms could help develop targeted therapies for reducing CVD risk in men with ED (Besiroglu et al., 2015 [5]; Vlachopoulos et al., 2013 [6]).

2. **Intervention Trials:**

Conduct randomized controlled trials to evaluate the effectiveness of interventions aimed at reducing CVD risk in men with ED. Potential interventions include lifestyle modifications, pharmacotherapy (e.g., phosphodiesterase type 5 inhibitors), and management of comorbid conditions such as diabetes and hypertension (Guo et al., 2010 [7]; Batty et al., 2010 [8]).

3. Population-Based Studies:

Expand research to include diverse populations with varying demographic characteristics (e.g., age, ethnicity) and health conditions. This approach will help determine the generalizability of the findings and identify population-specific risk factors and protective factors (Raheem et al., 2017 [4]; Cao et al., 2013 [13]).

4. Early Screening and Risk Assessment:

Develop and validate screening tools for early detection of CVD risk in men with ED. These tools could incorporate biomarkers, imaging techniques, and comprehensive risk assessment models to improve the accuracy and predictive value of ED as a marker for CVD (Allen & Walter, 2018 [3]; Terentes-Printzios et al., 2022 [11]).

5. Longitudinal Follow-Up Studies:

Implement long-term follow-up studies to assess the temporal relationship between ED and CVD, as well as the impact of early interventions on long-term cardiovascular outcomes. These studies should aim to clarify whether ED precedes the development of CVD and how modifying risk factors can alter disease progression (Banks et al., 2013 [16]; Inman et al., 2009 [15]).

6. Integration with Clinical Practice:

Encourage the integration of ED assessment into routine clinical practice for cardiovascular risk evaluation. This integration would involve training healthcare providers to recognize ED as a potential early indicator of CVD and to implement appropriate diagnostic and therapeutic strategies (Nehra et al., 2012 [10]; Shamloul & Ghanem, 2013 [18]).

Conclusion

This meta-analysis primary goal was to investigate if there was enough evidence demonstrating a direct association between erectile dysfunction (ED) and an increased risk of cardiovascular disease (CVD). The results were consistent across multiple prospective cohort and case-control studies, reinforcing the hypothesis that ED serves as a significant predictor of cardiovascular events. The robustness of these findings was confirmed through sensitivity analyses, which indicated that the observed associations were not significantly influenced by the inclusion of lower-quality studies or the presence of publication bias.

The systematic review and meta-analysis revealed that men with ED have a substantially higher risk of developing various cardiovascular conditions, including coronary artery disease, myocardial infarction, stroke, and cardiovascular mortality. This highlights the systemic nature of ED, which shares common pathophysiological mechanisms with CVD, such as endothelial dysfunction, oxidative stress, and chronic inflammation.

The clinical implications of these findings are profound. Healthcare providers should incorporate cardiovascular evaluations into the routine clinical assessment of men presenting with ED, given its potential role as an early marker for vascular impairment and elevated cardiovascular risk. This integrated approach could facilitate early detection and intervention, potentially mitigating the risk of severe cardiovascular events in this population.

Further research is warranted to elucidate the underlying mechanisms linking ED and CVD, to evaluate the efficacy of targeted interventions, and to validate ED as a clinical tool for cardiovascular risk stratification. Such efforts will contribute to the development of comprehensive strategies aimed at improving cardiovascular outcomes in men with ED, ultimately enhancing both sexual and cardiovascular health.

Ethical Statement:

All included studies obtained ethical approval from their respective institutional review boards or regulatory authorities, and informed consent was obtained from participants, as per the Declaration of Helsinki.

Data Availability Statement:

The data underlying this meta-analysis are available from the corresponding author upon request.

References

1. **Dong JY, Zhang YH, Qin LQ.** Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. *Journal of the American College of Cardiology*. 2011;58(13):1378-1385.
<https://doi.org/10.1016/j.jacc.2011.06.024>
2. **Chowdhury SR, Karim M, Ullah SMA.** Association between erectile dysfunction and cardiovascular disease: A systematic review. *Chattagram Maa-O-Shishu Hospital Medical College Journal*. 2019;18(2):31-36.
<https://banglajol.info/index.php/CMOSHMCI/article/view/47779>
3. **Allen MS, Walter EE.** Health-related lifestyle factors and sexual dysfunction: a meta-analysis of population-based research. *The Journal of Sexual Medicine*. 2018;15(4):458-475. <https://doi.org/10.1016/j.jsxm.2018.02.009>
4. **Raheem OA, Su JJ, Wilson JR.** The association of erectile dysfunction and cardiovascular disease: a systematic critical review. *American Journal of Men's Health*. 2017;11(3):478-491. <https://doi.org/10.1177/1557988316630305>
5. **Besiroglu H, Otunctemur A, Ozbek E.** The relationship between metabolic syndrome, its components, and erectile dysfunction: a systematic review and a meta-analysis of observational studies. *The Journal of Sexual Medicine*. 2015;12(6):1309-1318. <https://pubmed.ncbi.nlm.nih.gov/25872648/>
6. **Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis N, et al.** Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. *Circulation*:

Cardiovascular Quality and Outcomes. 2013;6(2):99-109.

<https://doi.org/10.1161/CIRCOUTCOMES.112.966903>

7. **Guo W, Liao C, Zou Y, et al.** Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies. *The Journal of Sexual Medicine*. 2010;7(8):2805-2816.
<https://academic.oup.com/jsm/article/7/8/2805/6848282>
8. **Batty GD, Li Q, Czernichow S, et al.** Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease) trial. *Journal of the American College of Cardiology*. 2010;56(23):1908-1913.
<https://doi.org/10.1016/j.jacc.2010.04.067>
9. **Gandaglia G, Briganti A, Jackson G, et al.** A systematic review of the association between erectile dysfunction and cardiovascular disease. *European Urology*. 2014;65(5):968-978. <https://doi.org/10.1016/j.eururo.2013.08.023>
10. **Nehra A, Jackson G, Miner M, et al.** The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. *Mayo Clinic Proceedings*. 2012;87(8):766-778.
<https://doi.org/10.1016/j.mayocp.2012.06.015>
11. **Terentes-Printzios D, Ioakeimidis N, Rokkas K, et al.** Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. *Nature Reviews Cardiology*. 2022;19(3):185-195. <https://doi.org/10.1038/s41569-021-00593-6>
12. **Osondu CU, Vo B, Oni ET, et al.** The relationship of erectile dysfunction and subclinical cardiovascular disease: A systematic review and meta-analysis. *Vascular Medicine*. 2018;23(1):9-21.
<https://doi.org/10.1177/1358863X17725809>

13. **Cao S, Yin X, Wang Y, et al.** Smoking and risk of erectile dysfunction: systematic review of observational studies with meta-analysis. *PLOS ONE*. 2013;8(4) <https://doi.org/10.1371/journal.pone.0060443>

14. **Zhao, S., Wang, J., Xie, Q., Liu, Y., Luo, L., Zhu, Z., Li, E., & Zhao, Z.** (2019). High prevalence of erectile dysfunction in men with psoriasis: evidence from a systematic review and meta-analysis. *International Journal of Impotence Research*, 31(1), 74–84. <https://doi.org/10.1038/s41443-018-0093-8>

15. **Inman BA, Sauver JLS, Jacobson DJ, et al.** A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. *Mayo Clinic Proceedings*. 2009;84(2):108-113. [https://www.mayoclinicproceedings.org/article/S0025-6196\(11\)60817-3/fulltext](https://www.mayoclinicproceedings.org/article/S0025-6196(11)60817-3/fulltext)

16. **Banks E, Joshy G, Abhayaratna WP, Kritharides L, et al.** Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality: a prospective cohort study. *PLOS Medicine*. 2013;10(1) <https://doi.org/10.1371/journal.pmed.1001372>

17. **Luo Y, Zhang H, Liao M, Tang Q.** Sex hormones predict the incidence of erectile dysfunction: from a population-based prospective cohort study (FAMHES). *The Journal of Sexual Medicine*. 2015;12(5):1165-1174. <https://pubmed.ncbi.nlm.nih.gov/25800960/> DOI: [10.1111/jsm.12854](https://doi.org/10.1111/jsm.12854)

18. **Mirone, V., Fusco, F., Cirillo, L., & Napolitano, L.** (2022). Erectile Dysfunction: From Pathophysiology to Clinical Assessment. In V. Mirone, F. Fusco, L. Cirillo, & L. Napolitano (Eds.), *Practical Clinical Andrology* (pp. 25-33) 2022. https://link.springer.com/chapter/10.1007/978-3-031-11701-5_3

19. **Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA.** Erectile Dysfunction and Subsequent Cardiovascular Disease. *JAMA*. 2005;294(23):2996-3002. <https://doi.org/10.1001/jama.294.23.2996>

20. **Inman BA, Sauver JL, Jacobson DJ, McGree ME, Nehra A, Lieber MM, Roger VL, Jacobsen SJ.** A Population-Based, Longitudinal Study of Erectile Dysfunction and Future Coronary Artery Disease. *Mayo Clin Proc.* 2009;84(2):108-113. <https://pubmed.ncbi.nlm.nih.gov/19181643/>
21. **Banks E, Joshy G, Korda RJ, Stavreski B, Soga K, Egger S, Day C, Clarke NE, Bauman A.** Erectile Dysfunction Severity as a Risk Marker for Cardiovascular Disease Hospitalisation and All-Cause Mortality: A Prospective Cohort Study. *PLoS Med.* 2013;10(1) <https://doi.org/10.1371/journal.pmed.1001372>
22. **Dong JY, Zhang YH, Qin LQ.** Erectile Dysfunction and Risk of Cardiovascular Disease: Meta-Analysis of Prospective Cohort Studies. *J Am Coll Cardiol.* 2011;58(13):1378-1385.DOI: [10.1016/j.jacc.2011.06.024](https://doi.org/10.1016/j.jacc.2011.06.024) <https://pubmed.ncbi.nlm.nih.gov/21920268/>
23. **Shamloul R, Ghanem H.** Erectile Dysfunction. *Lancet.* 2013;381(9861):153-165. [https://doi.org/10.1016/S0140-6736\(12\)60520-0](https://doi.org/10.1016/S0140-6736(12)60520-0)